Semi-annual Report for 2026
Filed with SSE · · 212 pages · Chinese
Chengdu Olymvax Biopharmaceuticals Inc. on 6ix
Earlier from Chengdu Olymvax Biopharmaceuticals
- Announcement on Convening the 2026 Semi-annual Performance Briefing
- Announcement on Pledge of Certain Shares Held by Shareholders Holding More Than 5% of the Shares
- Voluntary Disclosure Announcement on the Unblinding Results of the Phase III Clinical Trial of Recombinant Staphylococcus Aureus Vaccine (E. coli)
- Announcement on Voluntary Disclosure of Winning the Second Prize of the 2025 National Technological Invention Award
- Announcement on Receiving Government Subsidies
Later from Chengdu Olymvax Biopharmaceuticals
- Niutech Signs Agreement with Global Energy Major for Waste Plastic Pyrolysis Line to Produce SAF
- Announcement on Shareholding Reduction Plan of a Director and Senior Management Member
- (688319)"Chengdu Olymvax Biopharmaceuticals Inc."Announcement on Progress of Litigation
- (688319)"Chengdu Olymvax Biopharmaceuticals Inc."Announcement on Voluntary Disclosure of Receipt of the Phase III Clinical Study Summary Report for the Recombinant Staphylococcus aureus Vaccine (E. coli)
- (688319)"Chengdu Olymvax Biopharmaceuticals Inc."Report for Q3 2026
Follow Chengdu Olymvax Biopharmaceuticals into a list and get an email when it puts out news.
Follow Chengdu Olymvax Biopharmaceuticals